undamentalytics Newsletter
Sign in

Lineage Cell Therapeutics, Inc. cash flow statement

In fiscal 2025, Lineage Cell Therapeutics, Inc.'s operations generated −$18.9m of cash; it spent $522,000 on capital projects, leaving free cash flow of −$19.4m.

Cash flow statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2009Dec 20092010Dec 20102011Dec 20112012Dec 20122013Dec 20132014Dec 20142015Dec 20152016Dec 20162017Dec 20172018Dec 20182019Dec 20192020Dec 20202021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMJun 2026
Cash from operations−4−8−14−20−30−39−45−42−31−31−32−20−241−29−23−19−24
Depreciation and amortisation000011111111111111
Stock-based pay0122341184542445555
Capital spending001020121100001111
Free cash flow−4−8−15−20−32−39−46−45−32−31−32−20−241−29−24−19−24
Free cash flow after stock pay−5−9−16−22−35−44−57−53−36−37−36−22−27−4−34−29−24−29
Shares issued80012644352049—053107———

Free cash flow is cash from operations minus capital spending. Free cash flow after stock pay also subtracts stock-based compensation, a real cost to shareholders that the cash flow statement adds back. Dividends, buybacks and shares issued are cash amounts for the period.

Compare with peers

Head to head: ALEC vs LCTXLCTX vs SRZNKROS vs LCTX

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Lineage Cell Therapeutics, Inc.'s SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Lineage Cell Therapeutics, Inc.